Institutional investors hold a majority ownership of IMGN through the 91.62% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended March 2014, these large investors purchased a net $2.7 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
TFS CAPITAL LLC Bought 45.1 Thousand shares of ImmunoGen Inc
STONEBRIDGE CAPITAL MANAGEMENT, ... Bought 20.8 Thousand shares of ImmunoGen Inc